Johnson & Johnson (NYSE: JNJ) has announced positive results from the Phase III MDD3001 trial for seltorexant, a selective orexin-2 receptor antagonist.
The study showed significant improvements in depressive symptoms and sleep disturbances in patients with major depressive disorder and insomnia.
The trial success comes as J&J signaled its belief that seltorexant could become one of around 15 new assets with blockbuster potential.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze